

Sacituzumab govitecan TROPHY-U-01

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Sacituzumab govitecan TROPHY-U-01

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Genitourinary Cancers  
 Therapeutic Indication: Treatment of patients with locally advanced or metastatic UC who have previously received a platinum-containing ChT and either PD-1 or PD-L1 inhibitor  
 Experimental Arm: Sacituzumab govitecan  
 Control Arm: Single arm



